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Previous reports of children with co-existence of cystic fibrosis and full trisomy 21 suggest a very poor prognosis, with the majority of cases
dying in infancy and the oldest reported survivor being 6 years of age. We report the case of a young man with genetically confirmed trisomy 21
and homozygous for the F508del cystic fibrosis mutation. Despite the diagnosis of cystic fibrosis being delayed until the age of 2 years he has
transitioned to adult services and is now 25 years of age. Currently he has poor lung function and a continuous ambulatory oxygen requirement.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Trisomy 21; Cystic fibrosis1. Introduction
Reports of cases of children with both trisomy 21 and cystic
fibrosis are rare in the literature [1–3]. The documented outlook
has been extremely poor, with three such children dying as
infants, another before the age of two and the oldest reported
survivor aged six years and eleven months [1–3].
A further single case report of an 8% mosaic trisomy 21 and
cystic fibrosis has been reported and was making good clinical
progress at age seven [4].
The current available literature thus suggests a very poor
prognosis for full trisomy 21 co-existing with cystic fibrosis.
We report a case of genetically proven full trisomy 21 with
cystic fibrosis (genotype homozygous F508del mutation), who
with cystic fibrosis centre care, has survived through childhood
and transitioned to the adult cystic fibrosis clinic. He is now
twenty five years old. This case will help inform antenatal and
postnatal counselling given to parents of babies in whom these
two lifelong medical conditions are found to co-exist with regard
to prognosis and management.⁎ Corresponding author. Tel.: +44 113 3927125.
E-mail address: emma_clubley@hotmail.com (E.L. Guy).
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A diagnosis of trisomy 21 was made shortly after birth, on
the basis of clinical features, and was subsequently confirmed as
full trisomy 21 by chromosomal analysis. He was adopted and
first became unwell with two chest infections requiring hospital
admission between the ages of 21 and 26 months.
He was noted to have offensive fatty stools and had faltering
growth. He was diagnosed with cystic fibrosis at just over
2 years of age on the basis of a positive sweat test (sodium
106 mmol/L and chloride 140 mmol/L, with 309 mg of sweat)
and started on regular pancreatic enzymes, vitamins and
prophylactic trimethoprim. Faecal chymotrypsin was low at
this time, pancreatic insufficiency was later confirmed by faecal
elastase of 5 μg/g stool (normal rangeN200 μg/g). At the age of
2 and a half Pseudomonas aeruginosa was cultured from a
cough swab sample and he received a 10 day course of intra-
venous gentamicin.
He had a full assessment at our centre at the age of 3 years and
was already noted to have digital clubbing and evidence of chronic
changes on chest X-ray. Cough swab showed a heavy growth of
Staphylococcus aureus and Haemophilus influenzae, and he was
changed to prophylactic flucloxacillin and prescribed a treatment
course of amoxicillin.
Clinically he improved dramatically on pancreatic supple-
mentation and remained under regular medical follow up by hisd by Elsevier B.V. All rights reserved.
Table 1
Previously published case reports of children with probable co-existent trisomy 21 and cystic fibrosis. Not all cases are genetically confirmed.
Reference Method of trisomy 21 diagnosis Method of cystic fibrosis diagnosis Outcome
Milunsky [1] Clinical features Older sibling had CF, sweat test Died10/52
Milunsky [1] Clinical features Sweat test, absence of pancreatic enzymes in stool, post mortem Died 22/12
Milunsky [1] Chromosomes Sweat tests, (pancreatic sufficient) Alive at publication (age 6 years)
Vetrella et al. [2] Unclear Sweat test, absent pancreatic enzymes in duodenal secretions Died day 49
Kruger et al. [3] Chromosomes Sweat test, genetic— homozygous F508del mutation Died at 6/12
Saglani and Bush [4] 8% mosaic Genetic— homozygous F508del mutation Alive at publication (age 7 years)
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Cystic Fibrosis Centre.
At the age of 10 years he had increasing chest symptoms and
grew P. aeruginosa again, and had two courses of intravenous
anti-pseudomonal antibiotics. He continued to have productive
cough with FEV1 47% predicted, but was enjoying life and
attending mainstream school. A further unsuccessful attempt at
eradication was made with oral ciprofloxacin and nebulised
colomycin despite this chronic P. aeruginosa infection
developed.
At transition to adult services aged 18 years, spirometry
demonstrated a FEV1 of 1.46 (46% predicted) and FVC of 2.48
(73% predicted). Over the following seven years, FEV1 slowly
declined to 20% predicted. With regular intravenous antibiotics
every 3 to 4 months lung function remained stable for over
2 years. More recently he has required long term oxygen therapy.
MRSAwas eradicated from sputum. Following a discussion with
both the patient and his parents, a collective decision not to
proceed with referral for transplantation was made.
3. Discussion
We are aware of five previous cases of children with cystic
fibrosis and trisomy 21 reported in the literature, as well as a
child with 8% mosaic trisomy 21 (see Table 1). Whilst both
conditions in isolation are relatively common (UK incidence of
cystic fibrosis 1:2415 live births [5] and of trisomy 21, 1:1100
live births [6]), the expected incidence for both to co-exist in the
United Kingdom would be approximately 1:2,650,000. Thus
we would only expect to see a case with cystic fibrosis and
trisomy 21 every 3–4 years in England and Wales (using the
2008 birth rate).[7] The reported outlook for patients with full
trisomy 21 and cystic fibrosis has been very poor (Table 1).
As children with trisomy 21 are reported to have elevated
sweat osmolality, it is important to confirm the diagnosis of
cystic fibrosis by genotype if possible. [8]Our case is the longest reported survivor with genetically
confirmed cystic fibrosis and trisomy 21. As he was diagnosed
with cystic fibrosis at the age of 2 years on the basis of
symptoms, and developed chronic P. aeruginosa infection at
the age of 10 years, it would be hoped that outcomes for
children diagnosed with CF through newborn screening who
have trisomy 21 and who are treated comprehensively from
diagnosis may be better still.
In summary, despite the previous literature suggesting a very
poor prognosis, we can report a patient who has transitioned to
adult care with co-existing trisomy 21 and cystic fibrosis. We
hope that this will help paediatricians when counselling parents
regarding prognosis and management in the future.References
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